-
TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical
•
Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund. Founded in…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology
•
XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly RMB 100 million (USD 14 million) in a Series A financing round. The round was led by Legend Capital, with participation from existing investors TIgerYeah Capital, Proxima Ventures, Dalton Venture, and Tao Capital. The funds…
-
Kossel Medtech Secures Over $14 Million in Series B Financing to Boost International Expansion
•
Kossel Medtech (Suzhou) Co., Ltd., a company specializing in coronary and peripheral intervention medical devices, electrophysiology series products, and related accessories, has reportedly secured over RMB 100 million (USD 14 million) in a Series B funding round. The round was led by Fortune Capital, with additional investments from SIDVC, SND,…
-
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 75.35% controlling stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation for a consideration of HKD 400 million (USD 51 million). This strategic move signifies CGP’s expansion into a broader range…
-
Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round
•
Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from…
-
Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production
•
Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B++ funding round led by Tenykin Capital and Jiangsu Jinqiao Private Equity Fund. The fresh capital is earmarked for the expansion of…
-
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China. Under the terms of the agreement, Grand Life will serve as the sole marketing promotion…
-
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
•
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period, highlighting a pipeline of 12 assets poised to achieve blockbuster status, including three projected to exceed EUR 5 billion in sales. The French pharmaceutical giant anticipates generating over EUR 10 billion in annual pharmaceutical revenues…
-
Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding
•
Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100 million (approximately USD 13.9 million) in a Series A financing round led by Qiaojing Capital. The funding round also attracted participation from notable investors including Hongcheng Investment, RongTong Capital, Chiron Ventures, and Zhejiang Innovation and…
-
J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth
•
Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025,…
-
China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval
•
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for CFT8919, a metamorphic BiDA degradation agent licensed from U.S. firm C4 Therapeutics, Inc. (NASDAQ: CCCC). The study will focus on…
-
Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement with German pharmaceutical giant Merck KGaA for its in-house developed colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). According to the agreement, Merck will secure an exclusive license to commercialize pimicotinib in mainland China, Hong…
-
Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary
•
Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its footprint in the Chinese market with the full acquisition of Sandoz’s (SWX: SDZ) China subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. This acquisition will grant Aspen all commercial and intellectual property rights to the subsidiary’s existing…
-
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
•
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80 million in a Series A+ financing round co-led by Tencent Investment and YuanBio Venture Capital. The funding round also saw participation from Northern Light Venture Capital, C&D Emerging Industry Equity Investment, Yuanhe Holding, Shanghai Healthcare…
-
Bosscome Science & Technology Secures Series A Funding for Precision Medical Navigation Systems
•
Bosscome Science & Technology, a Chongqing-based developer of integrated optical and magnetic navigation systems, has reportedly secured “tens of millions” of renminbi in a Series A financing round led by Zhongxi Life Investment Partnership and Rayfund Investment. The funds raised will be allocated towards market promotion of its submillimeter level…
-
Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production
•
Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has reportedly secured nearly RMB 300 million (USD 42 million) in a Series A+ financing round, following its RMB 200 million (USD 28 million) Series A funding in August this year. The latest round was co-led…
-
Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure
•
German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance of USD 5.75 billion in bonds shortly before disclosing a significant setback in its late-stage pipeline. The company issued the 3 to 30-year maturity bonds on November 16, and then announced the early termination of…
-
Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round
•
Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200 million (USD 28 million) in a Series B+ financing round. The round was led by IMEIK Technology and China-US Green Fund, with additional investments from Jiayuan Fund, Chengdu Capital Group, Lanchi Ventures, and other parties.…
-
OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika
•
OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular intervention based in Shenzhen, is poised to acquire an 84% stake in Indonesia-headquartered PT Revass Utama Medika for a consideration between USD 10.08 million to USD 20.16 million. PT Revass Utama Medika, which is focused…
